Prosecutors allege Adam Wayne Owens violated an anti-kickback statute in a scheme to provide genetic cancer testing for ...

Five cancer drugs − Revlimid, Pomalyst, Imbruvica, Jakafi, and Ibrance − cost Medicare enrollees $11,000 to nearly $15,000 ...

Drugs used to treat cancer, diabetes and other chronic conditions are among 15 picked for negotiations that could result in ...

Medicare has chosen 15 prescription medications for price negotiations this year, building off a first round of negotiations ...

The hugely popular medications Ozempic and Wegovy​, used for diabetes and weight loss, will be included in the next round of ...

A new study examining the use of high-cost drugs among patients with colorectal cancer and non-small cell lung cancer found ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

Five cancer drugs − Revlimid, Pomalyst, Imbruvica, Jakafi, and Ibrance − cost Medicare enrollees $11,000 to nearly $15,000 per drug in 2023, according to a KFF analysis. What's more ...

The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, ...

The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, ...

An analysis of oncology drugs approved in the United States found that Medicare spending was predominantly driven by the market, not a drug’s therapeutic value.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.